key: cord-0784064-fgndk26k authors: Boyles, Glenn P.; Thung, Stephen; Gabbe, Steven G.; Landon, Mark B.; Costantine, Maged M. title: Practical Considerations for Pregnant Women with Diabetes and SARS-CoV-2 Infection date: 2020-08-17 journal: Am J Obstet Gynecol MFM DOI: 10.1016/j.ajogmf.2020.100210 sha: 751bcb6850d0a9ee3201a2f4a9e72f412155e9f7 doc_id: 784064 cord_uid: fgndk26k Abstract Epidemiological data available so far suggest that individuals with diabetes, especially when not well controlled, are at greater risk than the general population for SARS-CoV-2 morbidity such as acute respiratory distress syndrome, multiorgan failure, and mortality. Given the significance between COVID-19 and diabetes mellitus and the lack of pregnancy specific recommendations, we aim to provide some guidance and practical recommendations for the management of diabetes in pregnant women during the pandemic, especially for general obstetricians-gynecologists and non-obstetrician taking care of these patients. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first appeared in 25 Wuhan Province, China in December 2019 and thereafter rapidly spread across the globe. The 26 WHO declared the outbreak a global pandemic on March 11, 2020, and at the time of writing 27 (May 2020) , there were over 1.7 million confirmed cases and 100,000 deaths in the US alone. 1 The coronavirus disease 2019 (COVID-19) pandemic has created unprecedented challenges to 29 healthcare providers, including obstetrical services. 30 31 Pregnant women undergo immunologic and physiologic changes rendering them susceptible to 32 severe disease from viral infection, as has been observed with influenza, varicella, severe acute 33 respiratory syndrome (SARS-CoV), and Middle East respiratory syndrome (MERS). 2 Early data 34 from case series did not suggest markedly worse maternal and fetal outcomes with COVID- 19 35 infection, although severe illness did occur. For example, a systematic review (n=51) from Italy 36 reported one fetal death, one neonatal death, and no maternal deaths. 3 United States, 9 whereas gestational diabetes has an estimated incidence of at least 6%. 10 56 Academic and referral centers naturally report higher prevalence among their patient 57 populations. Rates vary between groups by race, ethnicity, and presence of obesity or other 58 components of metabolic syndrome, and are continuing to increase amidst the obesity 59 epidemic. 11 The consequences of maternal diabetes are far-reaching; diabetes increases the risk 60 for preeclampsia, cesarean section, uteroplacental insufficiency, stillbirth, growth restriction and 61 fetal macrosomia, and other adverse obstetric and neonatal outcomes. As the pandemic unfolds, 62 appropriately managing diabetes and diabetic complications in pregnant women with COVID-19 63 disease will be necessary to optimize maternal and fetal outcomes. Metformin is often continued in pregnancy in women with pregestational type 2 diabetes or used 104 as a primary therapy in the third trimester for gestational diabetes. Glyburide may also be used. 105 While not FDA-approved for pregnancy, these agents are commonly used and are regarded as 106 safe, and provide an alternative or supplement to insulin. 22 However, in women with COVID-19, 107 acute illness and dehydration along with metformin use may increase the risk of lactic acidosis; 108 therefore this medication should be discontinued. 17 Oral agents in general should likely be 109 discontinued in hospitalized patients, especially among those with moderate-severe disease, with 110 insulin being the preferred agent for maintenance of glycemic control. 23 input from maternal fetal medicine, neonatologists, and infectious disease specialists. 29 We 138 contend that it is logical to avoid antenatal late preterm corticosteroids (ALPS) altogether in 139 patients with diabetes with COVID-19, as ALPS have less compelling neonatal benefits. 30,31 140 141 Moreover, there is emerging data that dexamethasone administration may improve mortality and 142 other outcomes in hospitalized patients with COVID- 19 . In an open-label, randomized controlled 143 trial (RECOVERY trial), patients hospitalized with COVID-19 were randomly assigned to 144 receive oral or intravenous dexamethasone or usual care. In a preliminary report, patients who 145 required oxygen supplementation or invasive mechanical ventilation and received 146 dexamethasone had reduced 28-day mortality. This survival benefit was not seen, and 147 dexamethasone was possibly associated with harm, among those with milder disease not 148 requiring respiratory support. 32 While the RECOVERY trial was notable for including pregnant 149 and breast-feeding women (n=6), participants received dexamethasone at different dosing 150 intervals (6 mg daily for up to 10 days) than what is recommended to promote fetal lung 151 maturity. 33 In addition, participants were older (mean age >60 years) than pregnant women and 152 more than half had medical comorbidities. 32 Based on the above, in pregnant women hospitalized 153 with COVID-19, who meet the eligibility criteria of the RECOVERY trial and require 154 respiratory support, it would be reasonable to offer dexamethasone in accordance with the trial's 155 protocol. However, a careful discussion between the patient and maternal fetal medicine and 156 critical care physicians is recommended to address risks and benefits, given the possible maternal 157 risks of corticosteroids discussed above and the potential non-generalizability of evidence to this 158 specific patient population. concluded that pregnancies complicated by COVID-19 infection may be at higher risk for 163 adverse perinatal outcomes such as preterm birth, fetal distress, or perinatal death, but not fetal 164 growth restriction. 34 COVID-19 poses significant challenges to providing care for pregnant women, including those 188 with diabetes mellitus. We discussed some practical applications to improve and adapt the care 189 of these patients, despite the lack of data. We urge the scientific communities and professional Covid-19)--Cases in 195 the US Covid-19 and pregnancy Coronavirus disease 2019 during pregnancy: a 200 systematic review of reported cases Coronavirus disease 2019 (COVID-19) in pregnant women: A 203 report based on 116 cases Coronavirus disease 2019 infection among 206 asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an 207 affiliated pair of New York City hospitals Characteristics and outcomes of pregnant women Potential maternal and infant outcomes from (Wuhan) coronavirus 219 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human 220 coronavirus infections Preventable health and cost burden of adverse birth 222 outcomes associated with pregestational diabetes in the United States Trends in prevalence of diabetes 225 among delivery hospitalizations American College of Obstetrics and Gynecology (ACOG) Clinical Guidance Vital 230 surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus 231 diseases (COVID-19)-China Hospitalization for ambulatory-care-sensitive conditions in 240 Taiwan following the SARS outbreak: a population-based interrupted time series study Clinical outcomes of current medical approaches 243 for Middle East respiratory syndrome: A systematic review and meta-analysis Practical recommendations for the management of 246 diabetes in patients with COVID-19 Diabetic ketoacidosis in pregnancy Risk factors and 251 prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes COVID-19 infection may cause ketosis and 254 ketoacidosis Committee on Obstetric Practice. Committee Opinion 713: Antenatal corticosteroid therapy 286 for fetal maturation Outcome of coronavirus spectrum infections 289 (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis COVID-19: Hyperglycemia management. The Ohio State 292 Investigation, Writing -Original Draft; Stephen Thung: Writing -Review and Editing Writing -Review and Editing; Mark Landon: Writing -Review and Editing Maged Costantine: Conceptualization, Writing -Review and Editing, Supervision